DIGITAL-VAULT-SERVICES
15.4.2024 09:01:30 CEST | Business Wire | Press release
Digital Vault Services:
- Siemens chooses Digital Vault Services (DVS) for guarantee digitization.
- Collaboration with Digital Vault Services reflects Siemens commitment to innovation and efficiency.
- DVS’s Guarantee Vault Platform enables Siemens to optimize workflow efficiency and enhance security in guarantee management.
Siemens, a technology company focused on industry, infrastructure, transport, and healthcare, chooses Digital Vault Services for guarantee digitization, reflecting its dedication to innovation and efficiency. Through the integration of Digital Vault Services' innovative Guarantee Vault Platform (GVP), Siemens propels its digital transformation journey within its Guarantee Business, leveraging technology to optimize operations and enhance customer satisfaction.
The adoption of the Guarantee Vault will empower Siemens for streamlined and digitized guarantee processes. With GVP integrated into its operations, Siemens will benefit from GVP’s unchallenged capabilities to seamlessly connect to the entire guarantee ecosystem including all bank and insurance partners.
Gerhard Heubeck, Global Head Trade Finance Advisory at Siemens, commented, “We are pleased to announce our partnership with Digital Vault Services. As an active member of the working group, we have always been convinced of GVP's capabilities to significantly improve our collaboration and communication with our financial partners and to eliminate time-consuming, manual and paper-based processes. By leveraging GVP's innovative features, we can now engage in efficient, fast, and paperless interactions, while fully digitizing the end-to-end process from our organization through our financial partners to our valued customers. “
"We are thrilled to collaborate with Siemens, a key member of the working group that contributed to the development of our Guarantee Vault Platform," said Ludger Janßen, Co-CEO of Digital Vault Services. "Siemens commitment to innovation aligns perfectly with our mission to digitize the entire guarantee ecosystem and helps with the digital transformation of the financial industry. Together, we will drive significant advancements in guarantee processing efficiency and security."
Jaime Gimeno, Co-CEO of Digital Vault Services added: "With digital guarantees issued, secured and safekept on Guarantee Vault, Siemens and its customers are well positioned to achieve maximum efficiency and transparency. We do all this using best in class technology secured to ISO 27001 standards to keep our customers safe. We welcome Siemens to our network and look forward to working with them on their digitization journey."
About Digital Vault Services
Digital Vault Services GmbH revolutionizes the guarantee journey with its Guarantee Vault, boosting complete digitization. This solution offers a seamless, paperless experience, transforming the guarantee ecosystem end to end. Applicants can request all types of guarantees globally within one central tool, while banks and insurers securely issue and store guarantees. Beneficiaries enjoy seamless interaction and can manage and access the guarantees anytime. Innovative features such as beneficiary read confirmation and pre-approved wording libraries enhance processing speed, transparency, and efficiency. With top-tier security standards and API integration for seamless connectivity, DVS ensures a robust solution for all guarantee- business needs.
Founded in 2018 through collaboration with 16 industry participants, banks and insurers, Digital Vault Services has rapidly evolved. Since its launch in 2021, Guarantee Vault has gained strong traction in Germany and is now expanding into other European markets, including the Nordic countries, where future presence has already been announced. The company’s headquarters are located in Munich, Germany.
About Siemens
Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, transport, and healthcare. From more resource-efficient factories, resilient supply chains, and smarter buildings and grids, to cleaner and more comfortable transportation as well as advanced healthcare, the company creates technology with purpose adding real value for customers. By combining the real and the digital worlds, Siemens empowers its customers to transform their industries and markets, helping them to transform the everyday for billions of people. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a globally leading medical technology provider shaping the future of healthcare. In fiscal 2023, which ended on September 30, 2023, the Siemens Group generated revenue of €77.8 billion and net income of €8.5 billion. As of September 30, 2023, the company employed around 320,000 people worldwide. Further information is available on the Internet at www.siemens.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240412273459/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom